- Home
- PLRX vs EYPT Comparison
PLRX vs EYPT Comparison
Compare PLRX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | EYPT |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 1.5B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PLRX | EYPT |
|---|---|---|
| Price | $1.29 | $13.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.67 | ★ $31.80 |
| AVG Volume (30 Days) | 533.4K | ★ 1.3M |
| Earning Date | 03-11-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $3.91 |
| 52 Week High | $1.95 | $19.11 |
Technical Indicators
Market Signals| Indicator | PLRX | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 37.90 |
| Support Level | $1.12 | $12.05 |
| Resistance Level | $1.36 | $13.32 |
| Average True Range (ATR) | 0.07 | 1.01 |
| MACD | -0.00 | -0.34 |
| Stochastic Oscillator | 29.27 | 4.23 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.